Mumbai-based MOFSL's Siddhartha Khemka says he has a positive view on Bajaj Finance despite the recent sell-off in response to its in-line Q1 results. He said the addition of new products to its range of services should help the firm grow. Khemka also expects broad-based improvement in India's healthcare market, adding that the regulatory uncertainty which has hung over the sector has eased somewhat, with some pharma firms already reporting better numbers. Khemka says he prefers Sun Pharma rather than Cipla or other local pharma names.
